首页> 外文期刊>Cancer Medicine >BRAF V600E mutation analysis in fine‐needle aspiration cytology specimens for diagnosis of thyroid nodules: The influence of false‐positive and false‐negative results
【24h】

BRAF V600E mutation analysis in fine‐needle aspiration cytology specimens for diagnosis of thyroid nodules: The influence of false‐positive and false‐negative results

机译:细针假析细胞学标本中的BRAF V600E突变分析甲状腺结节诊断:假阳性和假阴性结果的影响

获取原文
           

摘要

Background The accurate evaluation of BRAF V600E mutation in preoperative fine‐needle aspiration cytology (FNAC) specimens is important for making management decisions in thyroid nodules (TNs). The aim of this study was to assess the false‐positive and false‐negative BRAF V600E mutations in thyroid FNAC specimens and their influence on diagnosis of TN. Methods This prospective study enrolled 292 nodules in 269 patients who underwent BRAF V600E mutation analysis using amplification refractory mutation system‐quantitative real‐time polymerase chain reaction (ARMS‐qPCR) both in FNAC specimens and formalin‐fixed, paraffin‐embedded (FFPE) tissue samples after surgery. The false‐positive and false‐negative mutations for BRAF V600E analysis using ARMS‐qPCR in FNAC specimens were recorded, with reference to the results of BRAF V600E mutation analysis using ARMS‐qPCR in FFPE tissue sample. Diagnostic performances of FNAC, BRAF V600E mutation analysis in FNAC specimens, BRAF V600E mutation analysis in FFPE tissue sample, and the combination of FNAC and BRAF V600E mutation analysis for predicting thyroid malignancy were assessed. Results The false‐positive and false‐negative mutations for BRAF V600E analysis using ARMS‐qPCR in FNAC specimens were 10.1% (19/189) and 7.1% (7/98), respectively. FNAC combined with preoperative BRAF V600E mutation analysis significantly increased the diagnostic sensitivity from 75.7% to 92.3%, and accuracy from 78.7% to 90.6% in comparison with FNAC alone (both P ??.001). No significant differences were found between the combination of FNAC and BRAF V600E mutation analysis in FNAC specimens and the combination of FNAC and BRAF V600E mutation analysis in FFPE tissue sample (sensitivity: 92.3% vs 91.9%; accuracy: 90.6% vs 91.3%; both P ??.05). Conclusions FNAC combined with preoperative BRAF V600E mutation analysis can significantly increase the diagnostic performance in comparison with FNAC alone. False‐positive and false‐negative BRAF V600E mutation results are found in preoperative FNAC specimens, whereas it does not affect the overall auxiliary diagnosis of TNs.
机译:背景技术术前细针空气学(FNAC)标本中BRAF V600E突变的准确评估对于在甲状腺结节(TNS)中的管理决策是重要的。本研究的目的是评估甲状腺FNAC标本中的假阳性和假阴性BRAF V600E突变及其对TN诊断的影响。方法该前瞻性研究在FNAC试样和福尔马林固定的石蜡包埋(FFPE)组织中使用扩增耐火突变体系 - 定量实时聚合酶链反应(Arms-QPCR)进行BRAF V600E突变分析的269名前瞻性研究。手术后样品。记录使用FFPE组织样品中使用ARM-QPCR的BRAF V600E突变分析的BRAF V600E分析的假阳性和假阴性突变分析。 FNAC试样中FNAC的诊断性能,FFPE组织样本中的BRAF V600E突变分析,评估了FFPE组织样本中的BRAF V600E突变分析,以及FNAC和BRAF V600E突变分析预测甲状腺恶性肿瘤的组合。结果FNAC标本中使用Arms-QPCR进行BRAF V600E分析的假阳性和假阴性突变分别为10.1%(19/189)和7.1%(7/98)。 FNAc联合术前BRAF V600E突变分析显着提高了75.7%至92.3%的诊断敏感性,并且与单独的FNAc(P?<001)的FNAc相比,精度为78.7%至90.6%。在FNAC样品中FNAC和BRAF V600E突变分析的组合没有发现显着差异,FFPE组织样品中的FNAC和BRAF V600E突变分析的组合(灵敏度:92.3%Vs 91.9%;准确度:90.6%Vs 91.3%;两者p?>?05)。结论FNAC联合术前BRAF V600E突变分析可以显着增加与单独的FNAC相比的诊断性能。在术前FNAC标本中发现了假阳性和假阴性BRAF V600E突变结果,而它不会影响TNS的整体辅助诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号